Incannex Healthcare Inc IXHL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026
Trading Information
- Previous Close Price
- $2.24
- Day Range
- $2.21–2.25
- 52-Week Range
- $2.16–14.91
- Bid/Ask
- $2.21 / $2.24
- Shares Outstanding
- 12.54M
- Market Cap
- $27.72M
- Volume/Avg
- 5,337 / 82,951
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 12
- Website
- https://www.incannex.com.au
Valuation
Metric | IXHL |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.42 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | IXHL |
|---|---|
Quick Ratio | 48.61 |
Current Ratio | 48.81 |
Interest Coverage | — |
Quick Ratio
IXHL
Profitability
Metric | IXHL |
|---|---|
Return on Assets (Normalized) | −16.96% |
Return on Equity (Normalized) | −18.13% |
Return on Invested Capital (Normalized) | −18.11% |
Return on Assets
IXHL
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|bxvk?LPd | LOCK|Ptry^ | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|M&jQLFB& | LOCK|zZ#& | $48B | |||
| Haleon PLC ADR HLN | LOCK|YgQm%c | LOCK|S$ | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|!p<R!K^$ | LOCK|n$ | $32B | |||
| Viatris Inc VTRS | LOCK|b^Z$%m! | LOCK|Ytw | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|qG | LOCK|<$ | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|?#Vs#L | LOCK|R$B | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|GQrg@?d | LOCK|#% | $6B | |||
| Perrigo Co PLC PRGO | LOCK|#DLc#< | LOCK|HzR | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|>jYTyX | LOCK|<YszK | $2B |
United States